

## References

### I-199

1. Ilumya™ [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. Revised 8/2018.
2. MICROMEDEX®SOLUTIONS Compendia. 2020. Tildrakizumab.
3. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Tildrakizumab.
4. Blauvelt A, Reich K, Papp K, et al. Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials. *Br J Dermatol*. 2018;179(3):615-622.
5. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2018;58(5):826-850.
6. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.
7. Reich K, Papp K, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. 2017;390(10091):276-288.
8. Tildrakizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists.
9. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
10. Elewski B, Menter A, Crowley J, et al. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. *J Dermatolog Treat*. 2020;31(8):763-768.